Multi-protein medicament for treating tumor

A tumor treatment and drug technology, applied in the treatment and prevention of tumors, can solve the problems of ignoring key changes, heterogeneity, malignant tumor metastasis rate and high mortality rate, and achieve the effect of improving survival rate and obvious therapeutic effect

Inactive Publication Date: 2009-07-22
NATUREGEN BIOTECH SHANGHAI
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, unremitting efforts are still needed to overcome the problems of high metastasis rate and fatality rate of malignant tumors.
[0005] On October 5, 2002, the National Institutes of Health (NIH), the Cancer Institute (NCI), the Centers for Disease Control and Prevention (CDC), the American Cancer Society (ACS), and the North American Association of Oncology Registries (NAACCR) jointly completed the "U.S. Cancer Status Annual Report", the columnist of American Fortune magazine (Fortune) made a summary review on the diagnosis and treatment of cancer (1975-2002) "Is Human Being a Loser in the Battle Against Cancer?" 》, suggesting that the high metastasis rate and mortality rate of malignant tumors are related to many factors: 1) heterogeneity of tumor cells; 2) multidrug resistance of tumor cells; 3) imperfect design of anticancer drugs, etc.
More recently, Professor David Linton of Cornell University and colleagues found that this view ignores critical changes in the body before cancer cells spread

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multi-protein medicament for treating tumor
  • Multi-protein medicament for treating tumor
  • Multi-protein medicament for treating tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] A preparation of a polyprotein tumor treatment drug, comprising the following steps and process conditions: Step 1: gene cloning, constructing a high-expression plasmid

[0035] 1. Select the best position for RhoGDI2, MUS81 and MDA-7 gene insertion at the mRNA level;

[0036] 2. Construct expression plasmids of the above genes;

[0037] 3. After the plasmid and bacteria are selected, the cDNA library or the above-mentioned genes that have been synthesized are digested with endonuclease respectively, put together and connected with T4 ligase, and the obtained recombinant plasmid is transformed into E. coli to obtain high expression of RhoGDI2 , the recombinant of MUS81 and MDA-7 recombinant protein;

[0038] Step 2: Fermentation of recombinant bacteria

[0039] Sequentially activate overnight, culture, and induce;

[0040] Step three:

[0041] 1. Apply ultrasonic pulverization method to crush the bacteria;

[0042] 2. Centrifuge the broken liquid at 20,000 rpm at 4...

Embodiment 2

[0048]The purified RhoGDI2, MUS81 and MDA-7 recombinant proteins, RhoGDI2 and MDA-7 recombinant proteins were treated with mouse subcutaneous tumors respectively, and the combination of these two groups of recombinant proteins induced tumor cell apoptosis was analyzed. The concentrations of the two groups of recombinant proteins were both 30ng / ml, see the results figure 1 , figure 2 and image 3 shown, where figure 1 is a schematic diagram of the size of subcutaneous tumors in mice before treatment, figure 2 It is a schematic diagram of the tumor treated with RhoGDI2 and MDA-7 protein, it can be seen that the tumor has shrunk, image 3 It is a schematic diagram of tumors in mice treated with MUS81, RhoGDI2 and MDA-7 proteins. It can be seen that the tumors have shrunk significantly. It can be seen from the above figures that the combination of these two groups of recombinant proteins has a strong effect of killing tumor cells, but the apoptosis rate of tumor cells treate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a polyprotein tumor comprehensive therapeutic medicine, which comprises tumor metastasis inhibition proteins, tumor inhibition proteins and a pharmaceutically acceptable vector or excipient. The polyprotein tumor comprehensive therapeutic medicine has more obvious effect compared with a single-protein therapeutic medicine.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a composition for treating and preventing tumor (cancer) and inhibiting tumor metastasis. Background technique [0002] As we all know, malignant tumor (cancer) is an increasingly serious threat to human health, has consumed a large number of human material resources and seriously endangered human life and health. According to statistics, there are more than 8 million new cancer patients and 6.2 million deaths every year in the world. In my country, there are more than 1.6 million new cancer patients and 1.6 million deaths every year. By 2020, the number will double. The number of patients will reach 84 million, which is a terrible number. [0003] Malignant tumors (cancers), which are different from benign tumors, are characterized by their ability to invade surrounding tissues. Cancer cells in the advanced stage of the disease metastasize remotely, destroy the invaded organs, and eve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P35/00
Inventor 裘建英张云福
Owner NATUREGEN BIOTECH SHANGHAI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap